Recently, US federal vaccine advisers decided to drop a proposal to stop mRNA COVID vaccine recommendations. This decision comes after some committee members under HHS Secretary Robert F. Kennedy Jr. sought to halt these immunizations. However, those specific plans are no longer moving forward. Consequently, the Centers for Disease Control and Prevention (CDC) will maintain its current immunization schedules for the time being.

Current Status of mRNA COVID Vaccine Recommendations

In September 2025, the Advisory Committee on Immunization Practices (ACIP) modified its official guidance. The committee scrapped broad recommendations and moved to a \"shared clinical decision-making\" model. This protocol applies to individuals aged six months and older. Under this framework, healthcare providers and patients decide on vaccination together. Therefore, doctors must discuss specific risks and benefits with each patient individually.

HHS Policy Shifts and Research Funding

Leadership changes at the Department of Health and Human Services (HHS) have impacted vaccine development. In August 2025, the HHS began winding down mRNA research activities. Secretary Kennedy Jr. cited concerns about the efficacy of mRNA platforms against upper respiratory infections. Specifically, the department terminated several contracts for mRNA flu and COVID-19 vaccines. Furthermore, no new federal funding will support mRNA-based projects. Instead, the department intends to focus on safer, broader vaccine platforms.

Clinical Impact for Healthcare Providers

The CDC advisers plan to meet next week to discuss future guidance. They will likely review data on vaccine injuries and long COVID. Physicians should continue following the 2025 immunization schedule until the CDC issues new updates. Clinical conversations should highlight that the risk-benefit ratio is most favorable for high-risk patients. Additionally, providers should ensure that informed-consent materials include clear language regarding potential risks and uncertainties.

Frequently Asked Questions

Q1: What is the latest update on US mRNA vaccine recommendations?

US vaccine advisers have dropped a recent push to stop recommending mRNA COVID-19 shots, keeping the current shared clinical decision-making model in place.

Q2: Who currently qualifies for mRNA COVID-19 vaccines under CDC guidelines?

The current guidelines recommend shared clinical decision-making for all individuals aged six months and older, with a focus on those at higher risk for severe disease.

Q3: How does the HHS currently view mRNA vaccine development?

HHS leadership has reduced funding for new mRNA research, shifting focus toward other vaccine technologies while maintaining existing clinical recommendations for current shots.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports - ETHealthworld


2. HHS. (2025). HHS Winds Down mRNA Vaccine Development Under BARDA.


3. CDC. (2025). ACIP COVID-19 Vote: Shared Clinical Decision-Making for Vaccination.